Literature DB >> 3259600

Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models.

M P Castelli1, P L Black, M Schneider, R Pennington, F Abe, J E Talmadge.   

Abstract

Human rIL-1 alpha and -1 beta are shown to increase significantly the CFU-culture activity in the spleen as well as at other sites after i.v. or i.p. administration. IL-1 can also significantly increase survival and can "rescue" a number of animals if administered either before or after lethal doses of cyclophosphamide or gamma-irradiation. The protective and reconstitutive activities of the rIL-1 are shown to correlate with increased CFU-culture frequency and total number, as well as increased cellularity in the bone marrow and peripheral blood, suggesting that this is one of their mechanisms of action. The sequence and timing of administration of human rIL-1 is critical for the protection or rescue of animals receiving DNA-damaging agents; maximal activity is achieved when IL-1 is given 20 h before insult or 48 h after alkylating agent administration. Minimal therapeutic activity is observed with IL-1 as a single agent for the treatment of metastatic disease compared with other biologic response modifiers including IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259600

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins.

Authors:  H E Broxmeyer; S Vadhan-Raj
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Interleukins. Clinical pharmacology and therapeutic use.

Authors:  W E Aulitzky; M Schuler; C Peschel; C Huber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

3.  Preclinical studies and future directions in the development of new hematologic growth factors.

Authors:  S Gillis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

4.  Exogenous tumor necrosis factor alpha and interleukin-1 alpha increase resistance to Salmonella typhimurium: efficacy is influenced by the Ity and Lps loci.

Authors:  P J Morrissey; K Charrier; S N Vogel
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Combination effect of recombinant human interleukin-1 alpha with antimicrobial agents.

Authors:  S Nakamura; A Minami; K Fujimoto; T Kojima
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Systemic treatment with murine recombinant interleukin-1 beta inhibits the growth and progression of malignant glioma in the rat.

Authors:  C D Rice; R E Merchant
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

7.  Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Authors:  Janice P Dutcher; Donna Neuberg; Michael B Atkins; William J Tester; Scott Wadler; James A Stewart; Abraham Chachoua; Lynn M Schuchter
Journal:  J Interferon Cytokine Res       Date:  2014-01-16       Impact factor: 2.607

8.  Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins.

Authors:  F Cominelli; C C Nast; R Llerena; C A Dinarello; R D Zipser
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

9.  Recombinant interleukin-1 alpha augments granuloma formation and cytokine production but not parasite clearance in mice infected with Leishmania donovani.

Authors:  A J Curry; P M Kaye
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.